Drug Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Drug Name PRS-343
Trade Name
Drug Descriptions

PRS-343 is a bispecific antibody targeting both CD137 (4-1BB) and Erbb2 (Her2), resulting in enhanced anti-tumor immune response against Erbb2 (Her2)-positive tumor cells (Eur J Cancer, Dec 2016, 69 (Suppl. 1): S99, abstract 301, PMID: 31138587).

DrugClasses HER2 (ERBB2) Antibody 58 TNFRSF9 Antibody 17
CAS Registry Number NA
NCIT ID C142890


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Therapy Name Drugs Efficacy Evidence Clinical Trials
Atezolizumab + PRS-343 Atezolizumab PRS-343 0 1
Paclitaxel + PRS-343 + Ramucirumab PRS-343 Paclitaxel Ramucirumab 0 1
PRS-343 PRS-343 0 1
PRS-343 + Tucatinib PRS-343 Tucatinib 0 1

Additional content available in CKB BOOST